The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non–small cell lung cancer

Cancer statistics, 2012

Rebecca L. Siegel, Deepa Naishadham, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2012 · 10.7K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee et al. · Science · 2004 · 9.4K citations

Medicine, Molecular Genetics, Oncology +17

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature · 2007 · 5.4K citations

Medicine, Molecular Biology, Oncology +14

Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

Ming‐Sound Tsao, Akira Sakurada, Jean-Claude Cutz et al. · New England Journal of Medicine · 2005 · 1.9K citations

Medicine, Oncology, Pharmacology +14

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

William Pao, Theresa Y. Wang, Gregory J. Riely et al. · PLoS Medicine · 2005 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +15